### Subject Index

| Acute-phase response, cytokine mediation in cachexia | 157, 158 |
| β2-Adrenergic agonist, effects on rat tumor models | 264 |
| Alcohol |  |
| breast cancer studies | 107, 108, 111, 112, 116 |
| β-carotene interactions | 53 |
| lung cancer studies | 30 |
| prostate cancer studies | 60 |
| Alcohol dehydrogenase, alleles in human cancer | 107, 116 |
| Anabolic competence, paradigm for nutritional intervention | 197, 198 |
| Angiogenesis, dietary modulation | 12, 20 |
| Animal models, nutrition in cancer studies |  |
| dietary approaches |  |
| amino acids | 176–178, 181 |
| chows | 174 |
| composition of diet | 174, 175 |
| energy intake | 174, 175, 181 |
| fatty acids | 178, 181, 182 |
| fiber | 181 |
| restricted diets | 175 |
| route of feeding | 174, 178, 179 |
| supplemented diets | 175–177 |
| extrapolation to humans |  |
| advantages of diverse models | 171, 172 |
| diversity of metabolic abnormalities | 172, 173 |
| protein metabolism regulators | 172–174 |
| insulin studies | 180–182 |
| selection factors | 167 |
| transgenic mouse | 13, 14 |
| treated, tumor-bearing models |  |
| chemotherapy | 169, 170, 181 |
| surgery | 170, 171, 182 |
| untreated tumor models |  |
| animal carcinogenesis models | 168 |
| human tumor cells | 168 |
| transplatable tumors | 168 |
| rats, tumor weight and anorexia | 168, 169 |
| Anorexia |  |
| cancer cachexia | 148, 149 |
| malnutrition in cancer | 226, 239 |
| AP-1, lung levels with β-carotene supplementation in animals | 47, 48 |
| Apoptosis |  |
| Bcl-2 role | 14 |
| dietary modulation | 10 |
| Arginine |  |
| clinical trials of immunonutrition | 260, 261 |
| nitric oxide effects | 260 |
| pediatric cancer patient supplementation | 281 |
| rationale for supplementation in cancer patients | 260, 273 |
| surgical cancer patient supplementation | 246 |
| Benzo(a)pyrene diol epoxide, scavenging by nutrients | 6 |
| Benzoyl peroxide, tumor promotion mechanisms | 8, 9 |
| Biomarkers, cancer trials | 285–291 |
| Bone marrow transplant, see Hematopoietic stem cell transplant |  |
Subject Index

Bradford Hill criteria, establishing causality 287, 288

Breast cancer
  breast feeding effects on maternal risk 115
dietary effects
  adolescence 105
  alcohol 107, 108, 111, 112, 116
  β-carotene 109, 110
  childhood 105, 112
  fat intake 106
  fiber 111
  folate 110, 116
  fruits and vegetables 108, 109, 111, 112
  infancy 104, 105, 115, 116
  soy protein 116
  vitamin A 109
  vitamin C 110
  vitamin E 110
epidemiology 103, 104
heredity 115
immigration studies 103, 104
premenopausal women studies 131, 132
sex hormone-binding globulin deficiency 120
Breast feeding
  infant diet effects on future breast cancer development 104, 105, 115
  lactation effects on breast cancer development 115

Cachexia
  asthenia 147, 155
  body composition changes 135, 141
  contributing factors with surgery 239, 240
cytokines
  acute-phase response mediation 157, 158
  food intake and malnutrition role 148, 149
  hypermetabolism role of tumor necrosis factor 151–153
  insulin resistance role 158, 159
  lipid metabolism role 153, 154, 163
  muscle wasting role 155–157
  overview 137, 147, 148, 159, 160
  protective cytokines 160
  therapeutic targeting 161, 163, 164
  weight loss induction
  ciliary neurotropic factor 151
  interferon-γ 150
  interleukin-6 150
  leukemia-inhibitory factor 150
  tumor necrosis factor 149–151, 160, 161
  insulin effects in animal models 180–182
  isolation of non-cytokine mediators 159
  medroxyprogesterone acetate treatment 141
  mortality in cancer 135, 147, 188
  palliative therapy 164, 165
  pediatric cancer patients
    consequences 276
    incidence 275, 282, 284
    pathogenesis 276
    pharmacotherapy 281, 282, 284
    risk factors 278
penoxythillin therapy 163
skeletal muscle loss
  eicosapentaenoic acid inhibition and therapy 140–142, 144, 145
  overview of mechanisms 136
  proteolysis-inducing factor assay 144
  evidence for muscle catabolism 136, 137
  glycosylation 138, 139
  isolation 137, 138
  lipid modulation 139, 140
  mechanism of action 139
  receptor 146
  regulation 144
  tumor specificity 144
  proteolytic pathways 139
Calcium
  colorectal cancer studies 76, 77
  prostate cancer studies 59, 60
Caloric restriction
  confounding factor in animal nutrition studies 20
  cycling effects 20
  historical perspective of cancer studies 21
  immune surveillance of malignant cell enhancement 11
  lifespan effects 20, 21
  mechanisms of carcinogenesis inhibition 18, 19
  protein kinase C effects 10
Cancer cachexia, see Cachexia
Cancer registry, data in nutritional epidemiology 117, 118
Carcinoembryonic antigen, marker in cancer trials 285
α-Carotene, lung cancer studies 27, 28
β-Carotene
alcohol interactions 53
breast cancer studies 109, 110
colorectal cancer studies 78–80
lung cancer studies
high-dose supplementation effects in smokers 42, 43, 45–49, 51
intervention studies 41, 42
mechanisms of prevention 41
oxidation products and carcinogenesis 43, 45
prospective cohort studies 24, 27, 28
vitamin C as reducing agent 50–52
vitamin E as reducing agent 50–52
metabolism in smokers 42, 43, 45, 48, 49, 54
prostate cancer studies 57, 58, 64, 65
Chemotherapy
classification of agents
alkylating agents 185, 186
antimetabolites 185, 186
examples 186, 187
hormones and antagonists 187
miscellaneous agents 187
natural products 185–187
historical perspective 183, 184
mechanisms in cancer 184, 185, 187
nutritional oncology
anabolic competence as paradigm for nutritional intervention 197, 198
attitudes of oncologists 203, 204
bidirectional interplay of nutrition and chemotherapy 195–197
gut translocation of bacteria 191, 192
historical perspective 188, 189
hormonal factors 204, 205
immune response 190–192
parenteral nutrition 189, 190, 202, 203
protein requirements 205
standardized nutritional assessment 192–194
supplements voluntarily taken by cancer patients 202
weight loss grading 192, 193
survival outcome 188, 189
withholding of nutrition 204
pediatric cancer patients 283
treated, tumor-bearing animal models 169, 170, 181
Children, see Pediatric cancer
Ciliary neurotropic factor, cachexia role, see Cachexia
CNERNA-CNRS-INRA, findings on diet and cancer 119
Coffee, colorectal cancer studies 81
Colorectal cancer
dietary effects
calcium 76, 77
β-carotene 78–80
coffee 81
dairy products 77
familial cancers 85, 86
fat intake
fat type effects 69
meat types, preparation, and processing 68–70
mechanisms 67, 68
fiber
mechanisms of protection 70
prospects for studies 72
sex differences 85
types of fiber 70, 71
folate
DNA integrity maintenance 92, 93
DNA methylation in mechanism 80, 90–92, 99, 100
DNA repair in mechanism 93, 94
epidemiologic studies 80
methylene tetrahydrofolate reductase polymorphisms 94–96
RNA methylation in mechanism 92
fruits and vegetables
animal studies 88
anticarcinogenic agents 72, 73
epidemiologic studies 72–74, 87
intervention trials 88
homocysteine 101
prospects for research 81, 82
Subject Index

selenium 79
sucrose 74, 75
tea 81
vitamin B6 100, 101
vitamin C 78, 79
vitamin D 77
vitamin E 78–80
epidemiology 67
exercise effects 86
markers 287
Committee on Medical Aspects of Food and Nutrition Policy, findings on diet and cancer 119
Cori cycle, activation in cachexia 151
Cyclooxygenase
inflammation role 10, 11
inhibition 11, 145
Cytochromes P450
carcinogen activation 3, 4
β-carotene metabolism in smokers 42, 43, 45, 48, 49, 54
Cytokines, see specific cytokines
Dairy products
colorectal cancer studies 77
prostate cancer studies 57
DNA methylation, folate inhibition in colon cancer 80, 90–92, 99, 100
DNA repair
dietary modulation 6
folate role in colon cancer 93, 94
Eicosapentaenoic acid, muscle catabolism inhibition in cachexia 140–142, 144, 145
Enteral nutrition
head and neck radiotherapy patients
body weight 227
effects with surgery and/or chemotherapy 230, 231
fat reserves 227, 229
lean body mass 227, 236
markers for metabolic changes 229
outpatients 232, 234, 235
parenteral nutrition and complications 234
percutaneous endoscopic gastrostomy 227, 229–232, 234–237
quality of life 229, 230, 234, 237
study design 227
hematopoietic stem cell transplant patients
children 218
complications 217
costs 217, 219
total parenteral nutrition 217–219
transition to oral diet 217, 218
tube placement 222, 223
pediatric cancer patients 277, 279
surgical cancer patients 243–245, 253
European Prospective Investigation into Cancer and Nutrition
aims 121, 122, 127
collaborating centers 121, 127–129
field work and subject recruitment 125, 126, 131
follow-up 126, 132
funding 131
sample storage 123, 125, 132, 133
study protocol 122, 123, 125, 132
Fat intake
breast cancer studies 106
colorectal cancer studies
fat type effects 69
meat types, preparation, and processing 68–70
mechanisms 67, 68
lung cancer studies 29, 30
prostate cancer studies 57, 63, 64
α-Fetoprotein, marker in cancer trials 285
Fiber
breast cancer studies 111
colorectal cancer studies
mechanisms of protection 70
prospects for studies 72
sex differences 85
types of fiber 70, 71
Flavonols, lung cancer studies 28, 29
Folate
breast cancer studies 110, 116
colorectal cancer studies
DNA integrity maintenance 92, 93
DNA methylation in mechanism 80, 90–92, 99, 100
DNA repair in mechanism 93, 94
epidemiologic studies 80
methylenetetrahydrofolate reductase polymorphisms 94–96
RNA methylation in mechanism 92
lung cancer studies 28
tissue distribution 89, 90
nucleic acid metabolism role 89, 90
296
Fruits and vegetables
  breast cancer studies 108, 109, 111, 112
  colorectal cancer studies
    animal studies 88
    anticarcinogenic agents 72, 73
    epidemiologic studies 72–74, 87
    intervention trials 88
  lung cancer studies 24, 25, 27–29, 33, 35, 36, 40
  prostate cancer studies 57, 58

Glutamine
  hematopoietic stem cell transplant
    patient treatment
      absorption 223
      clinical trials 211–215, 257, 258
      hepatic venocclusive disease effects 211, 215, 216
      infection outcomes 214, 215
      timing of therapy 216
      total parenteral nutrition 214
      tumor effects 215
      oral supplementation effects on chemotherapycinduced toxicity 257
      pediatric cancer patient supplementation 280, 281
      rationale for supplementation in cancer patients 256, 257
      surgical cancer patient supplementation 246, 247
      tumor utilization 255, 256
  Glutathione S-transferase, carcinogen detoxification 4, 5
  Growth hormone, anabolic effects in animal tumor models 263

Hematopoietic stem cell transplant
  allogeneic transplantation trends 208
  donors 207, 208
  graft-versus-host disease 208, 209, 216, 219, 220
  incidence 207
  nutrition
    body weight and outcomes 209, 210
    enteral feeding
      children 218
      complications 217
      costs 217, 219
    total parenteral nutrition 217–219
    transition to oral diet 217, 218
    tube placement 222, 223
  glutamine
    absorption 223
    clinical trials 211–215, 257, 258
    hepatic venocclusive disease effects 211, 215, 216
    infection outcomes 214, 215
    timing of therapy 216
    total parenteral nutrition 214
    tumor effects 215
    lipid modulation of graft-versus-host disease 219, 220
  related effects 209
  toxicity of marrow ablative regimens 210, 211

Homocysteine, colorectal cancer studies 101

Immunonutrition, see also Arginine, Glutamine, Omega-3 fatty acid, Ornithine-ß-ketoglutarate
  β2-adrenergic agonists 264
  ethical considerations 269
  formulations 264, 265
  hormones 263
  nutrient deficiencies in cancer patients 273
  study design 268
  surgical cancer patients
    gut-associated lymphoid tissue stimulation 252, 254
    perioperative 248, 249
    postoperative 246–248, 251, 252
    preoperative 252, 253
    randomized clinical trials 265–268

Initiation, tumors
  dietary modulation
    carcinogen activation 3, 4
    carcinogen detoxification 4, 5
    DNA repair 6
    scavenging of reactive oxygen species 5, 6
    overview 1, 2
  Insulin, anabolic effects in animal tumor models 263
  Insulin-like growth factors
    anabolic effects in animal tumor models 263
    cancer risk 120, 121
  Insulin resistance, cytokine mediation in cachexia 158, 159
  Interferon-γ, cachexia role, see Cachexia
  Interleukin-6, cachexia role, see Cachexia
Leukemia-inhibitory factor, cachexia role, see Cachexia
Lipoprotein lipase, cytokine regulation in cachexia 153, 154, 163
Lung cancer
dietary effects alcoholic 30
biases in studies 31, 32, 37 α-carotene 27, 28
β-carotene high-dose supplementation effects in smokers 42, 43, 45–49, 51
intervention studies 41, 42
mechanisms of prevention 41
oxidation products and carcinogenesis 43, 45
prospective cohort studies 24, 27, 28
vitamin C as reducing agent 50–52
vitamin E as reducing agent 50–52
fat intake 29, 30 flavonols 28, 29
folate 28
fruits and vegetables 24, 25, 27–29, 33, 35, 36, 40
lutein 27, 28
measurement error 32, 36, 37
multicollinearity of dietary variables 33
selenium 29
smoking as confounding factor in studies 32
vitamin C 24, 25, 27, 28
vitamin E 27
epidemiology 23
risk factors 23, 24, 39, 40
smoking carcinogens and oxidative damage 40
Lutein, lung cancer studies 27, 28
Meat, see Fat intake
Medroxyprogesterone acetate, cachexia treatment 141
Megestrol acetate, therapy in enteral nutrition during head and neck radiotherapy 231, 236, 238
Methylenetetrahydrofolate reductase, polymorphisms in colon cancer 94–96
Muscle loss, see Cachexia

Nutritional oncology
anabolic competence as paradigm for nutritional intervention 197, 198
attitudes of oncologists 203, 204
bidirectional interplay of nutrition and chemotherapy 195–197
gut translocation of bacteria 191, 192
historical perspective 188, 189
hormonal factors 204, 205
immune response 190–192
parenteral nutrition 189, 190, 202, 203
protein requirements 205
standardized nutritional assessment 192–194
supplements voluntarily taken by cancer patients 202
weight loss grading 192, 193
survival outcome 188, 189
withholding of nutrition 204

Obesity
measurements for cancer risk determination 120
prostate cancer risk 60, 63
tumor necrosis factor expression 164
Omega-3 fatty acid, see also Eicosapentaenoic acid
clinical trials of immunonutrition 263
pediatric cancer patient supplementation 281
rationale for supplementation in cancer patients 261
surgical cancer patient supplementation 246
Ornithine α-ketoglutarate
burn patient supplementation 258
rationale for supplementation in cancer patients 258, 259

p53
knockout mouse studies of nutritional modulation of cancer 13, 14
marker in cancer trials 290, 291
mutation in tumor progression 12

Patient-Generated Subjective Global Assessment of Nutritional Status
applications 193, 194
categorization of patients for nutritional intervention 194, 195
development 193
form 200
Pediatric cancer
malnutrition and cachexia
consequences 276
incidence 275, 282, 284
pathogenesis 276
pharmacotherapy 281, 282, 284
risk factors 278
nutritional support
chemotherapy patients 283
detrimental effects 279
enteral nutrition 277, 279
goals 277
long-term support 277, 278
parenteral nutrition 277, 280
short-term support 277
supplements
arginine 281
 glutamine 280, 281
omega-3 fatty acids 281
types of cancers 275
Pentoxyphyllin, cachexia treatment 163
Percutaneous endoscopic gastrostomy
head and neck radiotherapy patients 227, 229–232, 234–237
pediatric cancer patients 279
Progression, tumors
dietary modulation
angiogenesis 12
 cell proliferation and apoptosis 7–10
 immune surveillance 11
 inflammation 10, 11
 scavenging of reactive oxygen species 7
 overview 1, 2, 11, 12
Proliferating cellular nuclear antigen, lung levels with β-carotene supplementation in animals 46, 47
Promotion, tumors
dietary modulation
angiogenesis 12
 cell proliferation and apoptosis 7–10
 immune surveillance 11
 inflammation 10, 11
 scavenging of reactive oxygen species 7
 overview 1, 2
Prostate cancer
dietary effects
alcohol 60
calcium 59, 60
β-carotene 57, 58, 64, 65
dairy products 57
 fat intake 57, 63, 64
 fruits and vegetables 57, 58
 potential impact on incidence 62
 selenium 59, 63, 65
 study designs 56, 57
 vitamin D 59, 60
 vitamin E 58, 59, 63–65
 epidemiology 55
 risk factors 55, 56, 60
Protein kinase C
activation consequences 9
caloric restriction effects 10
phorbol ester interactions 8
Proteolysis-inducing factor
assay 144
evidence for muscle catabolism in cancer cachexia 136, 137
glycosylation 138, 139
isolation 137, 138
lipid modulation 139, 140
mechanism of action 139
receptor 146
regulation 144
tumor specificity 144
Radiotherapy
dietetic counseling 231, 233, 237
enteral nutrition during head and neck radiotherapy
body weight 227
effects with surgery and/or chemotherapy 230, 231
fat reserves 227, 229
lean body mass 227, 236
markers for metabolic changes 229
outpatients 232, 234, 235
parenteral nutrition and complications 234
percutaneous endoscopic gastrostomy 227, 229–232, 234–237
quality of life 229, 230, 234, 237
study design 227
indications for nutritional support 231, 233
megestrol acetate therapy 231, 236, 238
side effects causing malnutrition 226
Reactive oxygen species, dietary modulation of carcinogenesis
initiation 5, 6
promotion/progression 7
Resting energy expenditure, reduction with decreased food intake 239, 240
Retinoic acid receptor, lung levels with β-carotene supplementation in animals 48
Retinoids, effects on tumor promotion/progression 10
Selenium
- colorectal cancer studies 79
- lung cancer studies 29
- prostate cancer studies 59, 63, 65
Sensitivity, biomarker assays 286, 287, 289
Sex hormone-binding globulin, deficiency and breast cancer 120
Soy protein, breast cancer studies 116
Specificity, biomarker assays 286, 287, 289
Sucrose, colorectal cancer studies 74, 75
Surgery
- factors contributing to cachexia 239, 240
- malnutrition and outcomes 240, 241
- nutritional status assessment
  - anthropometrics 241, 242
  - clinical parameters 241
  - laboratory tests 242
- nutritional support
  - arginine supplementation 246
  - cost analysis 254
  - daily requirements 245, 246
  - glutamine supplementation 246, 247
  - immunonutrition
    - gut-associated lymphoid tissue stimulation 252, 254
    - perioperative 248, 249
    - postoperative 246–248, 251, 252
    - preoperative 252, 253
    - randomized clinical trials 265–268
- multimodal treatment 250
- omega-3 fatty acid supplementation 246
- overview 242
- routes
  - enteral nutrition 243–245, 253
  - formulas for tube feeding 244, 245, 253
  - total parenteral nutrition 244, 252
Tea, colorectal cancer studies 81
Tocopherols, see Vitamin E
Total parenteral nutrition
- hematopoietic stem cell transplant patients 217–219
- pediatric cancer patients 280
Total parenteral nutrition
cancer outcomes 202, 203
surgical cancer patients 244, 252
Transforming growth factor-α, activation by tumor promoters 9
Transgenic mouse, studies of nutritional modulation of cancer 13, 14
Tumor necrosis factor cachexia role, see Cachexia
expression in obesity 164
Uncoupling proteins, cachexia role 153
Vegetables, see Fruits and vegetables
Vitamin A, breast cancer studies 109
Vitamin B6, colorectal cancer studies 100, 101
Vitamin C
- breast cancer studies 110
- colorectal cancer studies 78, 79
- lung cancer studies 24, 25, 27, 28, 51
- lung tissue levels in smokers 54
- reduction of β-carotene 50–52
Vitamin D
colorectal cancer studies 77
prostate cancer studies 59, 60
Vitamin E
- breast cancer studies 110
- colorectal cancer studies 78–80
- lung cancer studies 27, 51
- prostate cancer studies 58, 59, 63–65
- reduction of β-carotene 50–52
World Cancer Research Fund/American Institute for Cancer Research, findings on diet and cancer 119